Isracann Biosciences Stock Total Debt
Isracann Biosciences fundamentals help investors to digest information that contributes to Isracann Biosciences' financial success or failures. It also enables traders to predict the movement of Isracann Pink Sheet. The fundamental analysis module provides a way to measure Isracann Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Isracann Biosciences pink sheet.
Isracann |
Isracann Biosciences Company Total Debt Analysis
Isracann Biosciences' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Based on the latest financial disclosure, Isracann Biosciences has a Total Debt of 0.0. This is 100.0% lower than that of the Healthcare sector and about the same as Drug Manufacturers—Specialty & Generic (which currently averages 0.0) industry. The total debt for all United States stocks is 100.0% higher than that of the company.
Isracann Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Isracann Biosciences' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Isracann Biosciences could also be used in its relative valuation, which is a method of valuing Isracann Biosciences by comparing valuation metrics of similar companies.Isracann Biosciences is currently under evaluation in total debt category among its peers.
Isracann Fundamentals
| Return On Equity | -2.53 | |||
| Return On Asset | -0.35 | |||
| Current Valuation | 2.16 M | |||
| Shares Outstanding | 175.99 M | |||
| Shares Owned By Insiders | 0.50 % | |||
| Price To Book | 9.57 X | |||
| Price To Sales | 8.83 X | |||
| EBITDA | (4.64 M) | |||
| Net Income | (4.69 M) | |||
| Cash And Equivalents | 310.61 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 0.76 X | |||
| Book Value Per Share | 0 X | |||
| Cash Flow From Operations | (1.75 M) | |||
| Earnings Per Share | (0.13) X | |||
| Beta | 0.12 | |||
| Market Capitalization | 2.45 M | |||
| Total Asset | 4.09 M | |||
| Z Score | -3.3 | |||
| Net Asset | 4.09 M |
About Isracann Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Isracann Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Isracann Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Isracann Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Isracann Pink Sheet
Isracann Biosciences financial ratios help investors to determine whether Isracann Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Isracann with respect to the benefits of owning Isracann Biosciences security.